The healthcare landscape is undergoing a transformation, propelled by technology and the imperative to address inequities. A new paradigm for patient access is emerging, moving beyond traditional clinic-centric models to a more decentralized, patient-empowered framework.
This analysis explores how the healthcare sector is innovating not only in therapeutic development, but also in delivery mechanisms that enhance access. By transitioning from intravenous infusions to self-administered subcutaneous injections and oral therapies, and through initiatives aimed at increasing inclusivity in clinical research, the healthcare sector is helping redefine patient access.
The traditional model of care delivery creates significant barriers for many patients. For example, 20% of rural residents live more than 60 miles from a medical oncologist, making frequent clinic visits for treatments like intravenous infusions a substantial burden.
Furthermore, systemic inequities persist in diagnostic testing. For patients with advanced non-small cell lung cancer, one in three do not receive guideline-recommended next-generation sequencing testing, with white patients receiving this testing at rates approximately 8% higher than their Black or Latino counterparts. These data underscore the dual challenge of geographic and systemic barriers—highlighting the need for integrated, patient-centered solutions.
The industry is contributing to the redefinition of drug delivery by shifting from resource-intensive IV infusions to subcutaneous injections and oral therapies. This evolution is a direct response to physical and logistical access barriers.
Many organizations have expanded their portfolios to include oral therapies, complemented by a growing list of subcutaneous products. This is made possible by advancements in technology that allow for the rapid dispersion of large drug volumes under the skin. This approach transforms time-intensive IV infusions into subcutaneous injections, a concept increasingly applied across oncology pipelines.
This strategic move not only reduces patient burden but also improves the efficiency of the healthcare system by freeing up clinic capacity and mitigating geographic barriers.
A top priority is to ensure that all clinically eligible patients, particularly those facing the greatest barriers to care, can access the medicines and care necessary for longer, healthier lives. A targeted approach is focused on expanding the ability to treat underserved patients by addressing these barriers and embedding equity into the delivery of medicines. There is a growing emphasis on embedding equity across every stage of the healthcare continuum from the design of clinical studies to how therapies are launched and commercialized, to investments in the communities served.
Data-driven approaches are increasingly being used to inform the inclusion of diverse patient populations, ensuring clinical trials reflect the broader patient population that experiences disease. For example, one multisite initiative aimed at inclusive research has demonstrated success in recruiting Black and Hispanic/Latino patients at twice the rate of comparable sites.
By supporting community-based organizations, the industry can drive community-led solutions, such as a cancer screening program for Black and Latina women. This multifaceted approach demonstrates a commitment to building a more trustworthy and equitable healthcare system from the ground up.
A strategic focus on accessible care offers a blueprint for the future of healthcare delivery. This patient-centric shift is gaining momentum across the industry, with other manufacturers who are also planning to introduce subcutaneous formulations in key oncology products. This broader industry commitment reflects a long-term investment in more accessible care models.
The future of care delivery demands a convergence of science, technology and equitable care for all. The advancement of self-administered therapies and equity-driven initiatives is at the forefront of this movement. By focusing on a shared vision to build a more accessible and equitable healthcare system for all, the industry is helping to ensure that the promise of life-changing medicine becomes a reality for every patient.
This content is sponsored by Genentech.
Leonard Scott, FACHE, is senior national account executive, National Supply & Care Delivery, and Paul Kinchak, DBA, is senior federal marketing manager, Genentech.
A Premier Corporate Partner of ACHE, Genentech has embodied a pioneering spirit with a legacy of innovation across science and medicines. For more information, visit ache.org/Genentech. M-US-00028824v1.0